Insulin-like growth factor II regulation of gene expression in rat and human hepatomas.
Insulin-like growth factor II (IGF II) regulated tissue-specific gene expression in hepatoma cell lines, but had no effect on expression of tissue-specific genes in primary cultures of E14 and newborn rat liver cells depleted of erythroid cells. No change was observed in these primary cultures with respect to alpha-fetoprotein (alpha-FP), albumin, cytokeratin 19 (CK19), gamma-glutamyltranspeptidase (GGT), and IGF II receptors. Two well-differentiated hepatoma, HepG2 and FTO-2B, and a poorly differentiated hepatoma, H4AzC2, did not show increased proliferation in the presence of IGF II, yet showed gene expression changes in response to IGF II. In HepG2 cells, IGF II increased albumin mRNA levels and resulted in a shift from clusters of cells positive to 100% of the cells expressing immunohistochemically detectable albumin. The transcription factor HNF-3 beta mRNA and protein levels of the bile duct markers, CK19 and GGT, were also increased in the presence of IGF II. Other genes tested were not affected, including alpha-1-antitrypsin, and two liver-specific transcription factors, HNF-4 and HNF-3 alpha. In FTO-2B cells, IGF II increased the expression of albumin, CK19, and GGT, without accompanying changes in albumin and GGT mRNAs. In H4A7C2 cells, IGF II reduced CK19 and OC.3 protein levels and GGT, transferrin, and HNF-3 beta mRNAs. The effects of IGF II on H4AZC2 cells were not blocked in the presence of an anti-rat IGF II receptor antibody. We conclude that IGF II affects tissue-specific gene expression of hepatomas and qualitative and quantitative aspects of its influence on the hepatomas is dependent on their degree of differentiation.
Zvibel
I
I
Albert Einstein College of Medicine, Department of Molecular Pharmacology, Bronx, New York 10461.
Brill
S
S
Reid
L M
LM
D000418:Albumins / Q000032:analysis / Q000235:genetics; D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000737:chemistry / Q000235:genetics / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D007335:Insulin-Like Growth Factor II / Q000494:pharmacology*; D007633:Keratins / Q000032:analysis / Q000235:genetics; D008113:Liver Neoplasms / Q000737:chemistry / Q000235:genetics* / Q000473:pathology*; D008114:Liver Neoplasms, Experimental / Q000737:chemistry / Q000235:genetics* / Q000473:pathology*; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D051381:Rats; D011916:Rats, Inbred F344; D017527:Receptor, IGF Type 2 / Q000032:analysis / Q000235:genetics; D014168:Transferrin / Q000032:analysis / Q000235:genetics; D014407:Tumor Cells, Cultured; D000509:alpha-Fetoproteins / Q000032:analysis / Q000235:genetics; D005723:gamma-Glutamyltransferase / Q000032:analysis / Q000235:genetics
D000418:Albumins; D012333:RNA, Messenger; D017527:Receptor, IGF Type 2; D014168:Transferrin; D000509:alpha-Fetoproteins; D007335:Insulin-Like Growth Factor II; D007633:Keratins; D005723:gamma-Glutamyltransferase